Equities research analysts expect Abeona Therapeutics Inc (NASDAQ:ABEO) to post $1.02 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Abeona Therapeutics’ earnings, with estimates ranging from $200,000.00 to $1.81 million. Abeona Therapeutics posted sales of $220,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 363.6%. The firm is expected to announce its next quarterly earnings report on Wednesday, November 21st.
According to Zacks, analysts expect that Abeona Therapeutics will report full-year sales of $6.08 million for the current financial year, with estimates ranging from $5.63 million to $6.83 million. For the next financial year, analysts forecast that the firm will post sales of $18.32 million per share, with estimates ranging from $4.23 million to $43.30 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.06). The business had revenue of $0.82 million during the quarter, compared to analysts’ expectations of $1.81 million. Abeona Therapeutics had a negative net margin of 881.74% and a negative return on equity of 23.02%.
ABEO has been the topic of a number of research reports. Zacks Investment Research raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. HC Wainwright set a $30.00 price target on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research note on Monday, August 13th. Maxim Group reaffirmed a “buy” rating and issued a $35.00 price target on shares of Abeona Therapeutics in a research note on Friday, August 10th. BidaskClub downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 26th. Finally, Cantor Fitzgerald set a $36.00 price target on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. Abeona Therapeutics currently has an average rating of “Buy” and a consensus price target of $28.30.
Shares of NASDAQ ABEO traded down $0.15 during mid-day trading on Thursday, reaching $14.35. The company had a trading volume of 352,500 shares, compared to its average volume of 910,020. Abeona Therapeutics has a twelve month low of $10.50 and a twelve month high of $22.75. The company has a market capitalization of $683.19 million, a PE ratio of -21.74 and a beta of 1.22.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Northern Trust Corp increased its position in Abeona Therapeutics by 1.3% during the first quarter. Northern Trust Corp now owns 304,434 shares of the biopharmaceutical company’s stock worth $4,369,000 after buying an additional 3,941 shares during the last quarter. BlackRock Inc. increased its position in Abeona Therapeutics by 0.3% during the first quarter. BlackRock Inc. now owns 1,873,472 shares of the biopharmaceutical company’s stock worth $26,884,000 after buying an additional 5,094 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Abeona Therapeutics by 11.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 62,852 shares of the biopharmaceutical company’s stock worth $902,000 after buying an additional 6,500 shares during the last quarter. Fortaleza Asset Management Inc. acquired a new position in Abeona Therapeutics during the second quarter worth $104,000. Finally, Knott David M acquired a new position in Abeona Therapeutics during the first quarter worth $101,000. 76.24% of the stock is currently owned by institutional investors and hedge funds.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
See Also: Average Daily Trade Volume Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.